Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01603095 · ClinicalTrials.gov registry record
A Multicenter, Multinational Clinical Assessment Study for Pediatric Patients With Achondroplasia
A clinical trial of Achondroplasia, sponsored by BioMarin Pharmaceutical.
- Completed
- Registry status
- 363
- Enrollment target
- 20
- Study locations
NCT01603095: Completed study of Achondroplasia, sponsored by BioMarin Pharmaceutical.
NCT01603095 is a study of Achondroplasia that has completed, run by BioMarin Pharmaceutical. The registered enrollment target is 363 participants, above the 111-participant average among 9 other Achondroplasia trials with a reported enrollment target (227% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01603095, a study of Achondroplasia, has completed, sponsored by BioMarin Pharmaceutical.
- COMPLETED
- Registry status
- 363 participants
- Enrollment target
- 20
- Study locations
Study Summary
Multicenter, multinational study to collect consistent baseline growth measurements on pediatric patients with Achondroplasia being considered for subsequent enrollment in future studies sponsored by BioMarin. No study drug is administered.
Primary Outcome
Patients will be screened and undergo a series of growth measurements on Day 1 and every 3 months thereafter. No study drug is administered.
Conditions Studied
Study Locations (20)
Other
- The Children's Hospital at Westmead - Westmead
- Osaka University Hospital - Osaka
- Saitama Children's Medical Center - Saitama
- Tokushima University Hospital - Tokushima
- Institut Catala de Traumatologica I Medicina de l'Esport - Barcelona
- Hospital Sant Joan de Deu Barcelona - Barcelona
- Hospital Universitario Virgen de la Victoria - Málaga
- Acibadem University School of Medicine - Istanbul
- Guy's and St. Thomas NHS Foundation Trust Evelina Children's Hospital - London
- Sheffield Children's NHS Foundation Trust - Sheffield
California
- Harbor-UCLA Medical Center - Los Angeles
- Children's Hospital and Research Center Oakland - Oakland
Delaware
- Nemours/Alfred I. duPont Hospital for Children - Wilmington
Georgia
- Emory University - Decatur
Illinois
- Ann and Robert H Lurie Children's Hospital of Chicago - Chicago
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Tennessee
- Vanderbilt University - Nashville
Texas
- Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 363 participants |
| Start Date | 2012-04 |
| Est. Completion | 2021-02 |
What the finished NCT01603095 record still lists
NCT01603095 is an observational study that tracks outcomes without assigning an intervention. The registered 363 participants enrollment target is mid-sized for trials with a published cap, above the 111-participant average among 9 other Achondroplasia trials with a reported enrollment target (227% higher).
The record links to 1 condition, with Achondroplasia appearing as the primary indexed condition, and to 0 interventions.
NCT01603095 names 20 study sites across 10 states, led by Other, California, Delaware.
Frequently Asked Questions
What is clinical trial NCT01603095 about?
NCT01603095 is a clinical study titled "A Multicenter, Multinational Clinical Assessment Study for Pediatric Patients With Achondroplasia". Multicenter, multinational study to collect consistent baseline growth measurements on pediatric patients with Achondroplasia being considered for subsequent enrollment in future studies sponsored by BioMarin. No study drug is administered.
What is the current status of trial NCT01603095?
This trial is currently completed. The enrollment target is 363 participants. The study started on 2012-04. Estimated completion is 2021-02.
What conditions does trial NCT01603095 study?
This clinical trial studies the following conditions: Achondroplasia.
Who is sponsoring clinical trial NCT01603095?
This trial is sponsored by BioMarin Pharmaceutical, which has 80 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01603095 being conducted?
This trial has 20 study locations across California, Delaware, Georgia, Illinois, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Achondroplasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01603095's enrollment target sits among peer trials
363 1st of 9 higher than 9 of 9 other Achondroplasia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Achondroplasia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)
RECRUITING · Phase 2
-
A Study of TYRA-300 in Children With Achondroplasia: BEACH301
RECRUITING · Phase 2
-
VIrtual STudy in Achondroplasia for the US (VISTA)
RECRUITING
-
A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia
RECRUITING · Phase 2
-
An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06472245 · 363 participants · Phase 3
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
- NCT04510597 · 364 participants · Phase 3
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
- NCT05098132 · 364 participants · Phase 1
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
- NCT05330221 · 364 participants · NA
Project 2: ACHIEVE- HF
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia